 This is an investigational study. Vorinostat is FDA approved and commercially available for the treatment of cutaneous T-cell lymphoma CTCL. Temsirolimus is FDA approved and commercially available for the treatment of kidney cancer. The use of these drugs in combination is investigational. The radiation therapy is delivered using FDA-approved and commercially available methods. 